GlassScriptPhysician profile
Alfredo Hernandez
NPI 1295856193
$11,889.62
in general payments reported to CMS, 2019-2025
46 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2020: $705 · 2021: $1,835 · 2022: $2,011 · 2023: $1,553 · 2024: $1,874 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,559 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.15 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,100.90 | 2019-2025 | |
| Janssen Biotech, INC. | $1,923.29 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $1,404.86 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $780.97 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $643.82 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $468.70 | 2019-2022 | |
| Genzyme Corporation | $455.36 | 2022-2025 | |
| Celgene Corporation | $352.30 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $338.77 | 2020-2025 | Ocaliva |
| Pfizer INC. | $338.52 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $279.20 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $272.31 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $264.70 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $244.14 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $240.06 | 2022-2025 | Dupixent |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.